GlassScriptPhysician profile
Richard M Arnold
NPI 1750300380
$8,384.74
in general payments reported to CMS, 2019-2025
29 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $217 · 2021: $997 · 2022: $1,348 · 2023: $2,805 · 2024: $1,827 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,924 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,924.01 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,579.94 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $961.05 | 2022-2023 | Tepezza |
| Novo Nordisk INC | $870.15 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Intra-Sana Laboratories | $760.88 | 2023-2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Astrazeneca Pharmaceuticals LP | $677.03 | 2019-2023 | Farxiga |
| Amgen INC. | $647.11 | 2019-2024 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $445.28 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $377.23 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $312.37 | 2021-2024 | |
| Beta Bionics, INC. | $304.29 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $303.35 | 2019-2024 | Viberzi, Linzess |
| Merck Sharp & Dohme LLC | $206.80 | 2019 | |
| Corcept Therapeutics | $200.92 | 2021-2023 | Korlym |
| Abbott Laboratories | $127.77 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $100.23 | 2020-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $89.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.34 | 2024 | Xifaxan, Trulance |
| Insulet Corporation | $51.10 | 2019-2023 | Omnipod |
| Radius Health, INC. | $47.31 | 2024 | Tymlos |
| Ultragenyx Pharmaceutical INC. | $40.85 | 2021 | |
| Ironwood Pharmaceuticals, INC | $40.85 | 2020-2024 | |
| Mannkind Corporation | $34.62 | 2019-2022 | |
| Antares Pharma, INC. | $31.50 | 2021-2022 | |
| Ibsa Pharma INC. | $29.23 | 2021-2024 | Licart, Flector |
| Kyowa Kirin, INC. | $20.80 | 2023 | Crysvita |
| Amneal Pharmaceuticals LLC | $19.61 | 2022 | |
| Endo Pharmaceuticals INC. | $19.40 | 2019 | |
| Allergan, INC. | $17.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.